Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $155,342.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $70.61, for a total value of $155,342.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Monday, May 12th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $72.06, for a total transaction of $158,532.00.
• On Thursday, April 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The stock was sold at an average price of $70.22, for a total transaction of $154,484.00.

Corcept Therapeutics Price Performance

NASDAQ CORT traded down $1.12 during trading on Friday, hitting $70.06. 1,008,383 shares of the stock traded hands, compared to its average volume of 1,148,777. The firm has a 50-day simple moving average of $71.49 and a 200-day simple moving average of $64.23. Corcept Therapeutics Incorporated has a 12-month low of $28.04 and a 12-month high of $117.33. The company has a market capitalization of $7.43 billion, a P/E ratio of 55.60 and a beta of 0.19. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. The firm had revenue of $157.21 million for the quarter, compared to the consensus estimate of $177.93 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.25 EPS. As a group, analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Institutional Trading of Corcept Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio lifted its position in shares of Corcept Therapeutics by 269.9% in the 4th quarter. Public Employees Retirement System of Ohio now owns 2,859 shares of the biotechnology company's stock worth $144,000 after purchasing an additional 2,086 shares during the period. Van ECK Associates Corp acquired a new position in shares of Corcept Therapeutics in the 4th quarter valued at $4,483,000. HighTower Advisors LLC lifted its holdings in shares of Corcept Therapeutics by 30.7% during the fourth quarter. HighTower Advisors LLC now owns 93,677 shares of the biotechnology company's stock worth $4,720,000 after purchasing an additional 22,011 shares during the period. New York State Teachers Retirement System increased its stake in shares of Corcept Therapeutics by 3.0% in the fourth quarter. New York State Teachers Retirement System now owns 128,232 shares of the biotechnology company's stock worth $6,462,000 after acquiring an additional 3,789 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Corcept Therapeutics by 2.7% in the 4th quarter. JPMorgan Chase & Co. now owns 259,902 shares of the biotechnology company's stock valued at $13,096,000 after buying an additional 6,832 shares during the period. 93.61% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CORT shares. Truist Financial set a $135.00 price target on Corcept Therapeutics in a research report on Tuesday, May 6th. HC Wainwright decreased their price target on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Wall Street Zen downgraded shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Piper Sandler upped their target price on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a report on Thursday, April 3rd. Finally, Canaccord Genuity Group boosted their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $138.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.